Inhaled and nasal budesonide are generally considered safe during pregnancy, with the most human safety data of any inhaled corticosteroid. Oral budesonide, used for inflammatory bowel disease, carries less certainty because far fewer pregnant women have been studied, but early evidence is reassuring. The answer depends heavily on which form you’re using and what condition it’s treating.
Safety Differs by Formulation
Budesonide comes in three main forms: inhaled (for asthma), nasal spray (for allergies), and oral or rectal (for Crohn’s disease or ulcerative colitis). Both the inhaled and nasal versions carry a Pregnancy Category B rating, meaning animal studies showed no harm at expected human doses and the available human data supports safety. The oral extended-release form, however, is rated Pregnancy Category C, meaning animal studies did show risks and human data is limited.
This distinction matters because systemic absorption varies dramatically. The nasal spray delivers roughly 34% of its dose into your bloodstream, and the resulting blood levels are about six times lower than what you’d get from the inhaled version. Oral budesonide, by contrast, is designed to act locally in the gut but delivers more of the drug systemically. The more drug that reaches your bloodstream, the more reaches the fetus.
Inhaled Budesonide Has the Strongest Safety Record
A large population-based study of 2,968 pregnant women who used inhaled budesonide in early pregnancy found completely normal outcomes. Babies were born at normal gestational age, with normal birth weight and length. There was no increase in stillbirths. The only difference was a slightly higher rate of cesarean deliveries among women using asthma medication, which may reflect the underlying asthma rather than the drug itself.
First-trimester exposure has been studied specifically for the risk of birth defects. A study examining inhaled corticosteroids (including budesonide) during the first 12 weeks of pregnancy found no increased risk of congenital malformations at low-to-moderate doses. At standard doses up to 1,000 micrograms per day, the odds of any malformation were actually lower than the baseline rate. Only at very high doses (above 1,000 micrograms per day) did the data become uncertain, though even then, no statistically significant increase was found.
This is why inhaled budesonide is the preferred inhaled corticosteroid for asthma management during pregnancy. No other inhaled steroid has this volume of reassuring human data.
Nasal Spray Appears Safe at Standard Doses
Data from over 2,100 infants born to mothers who used intranasal budesonide in early pregnancy showed a birth defect rate of 4.5%, compared to the general population rate of 3.5%. After statistical adjustment, the difference was not significant, with an odds ratio of 1.06. Since the nasal spray delivers substantially less drug to the bloodstream than even the inhaled form, this finding is consistent with what researchers would expect.
No systemic corticosteroid side effects were reported in clinical trials of the nasal spray. If you’re using budesonide nasal spray for seasonal or year-round allergies, the systemic exposure to your baby is extremely low.
Oral Budesonide Has Less Data but Early Signs Are Positive
For women with Crohn’s disease, the picture is less clear simply because fewer women have been studied. A case series of eight women who took oral budesonide (at doses of 6 to 9 milligrams daily) throughout pregnancy reported no congenital abnormalities in any of the babies. None of the mothers developed adrenal suppression, blood sugar problems, or high blood pressure. Treatment lasted between one and eight months.
Eight patients is a small number, and the FDA label for oral budesonide reflects this uncertainty. It states that human data is “insufficient to inform a drug-associated risk for major birth defects and miscarriage” and notes that animal studies using injected budesonide caused fetal loss and skeletal abnormalities. Those animal doses, however, were administered by injection (which bypasses the gut and liver), making direct comparison to oral doses in humans difficult.
The background risk of major birth defects in any pregnancy is 2% to 4%, and miscarriage occurs in 15% to 20% of recognized pregnancies, regardless of medication use. These baseline numbers provide important context when weighing the risks of any drug.
Untreated Conditions Carry Their Own Risks
The safety question isn’t just about the drug. It’s about what happens without it. Uncontrolled asthma during pregnancy is linked to a 48% increased risk of preterm birth compared to non-asthmatic women. Babies born to mothers with poorly managed asthma are more likely to have low birth weight, possibly because asthma attacks reduce oxygen supply to the fetus and alter blood flow through the placenta. Preeclampsia rates are also higher.
In one study, 12.9% of women with asthma delivered preterm, and 15.9% of their babies were small for gestational age. These risks persist even after accounting for smoking and other factors. For Crohn’s disease, active flares during pregnancy similarly raise the odds of preterm delivery and low birth weight. In both cases, the risks of uncontrolled disease often outweigh the theoretical risks of budesonide, particularly for the inhaled and nasal forms where systemic exposure is minimal.
Budesonide and Breastfeeding
Budesonide passes into breast milk in very small amounts. A fully breastfed infant would receive a maximum of 0.3% of the mother’s weight-adjusted dose from the inhaled form, assuming the baby absorbs 100% of what’s in the milk. Since budesonide is only about 9% absorbed when swallowed, the actual systemic dose reaching the infant after oral budesonide use is closer to 0.27%. For rectal formulations, the infant’s exposure drops to roughly 0.025%. These numbers are well below the thresholds that raise concern during breastfeeding.